ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Alpha Cognition Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.50+0.31 (+3.79%)
Close on Oct 19, 2026
- Market cap
- $185.08M
- P/E (TTM)
- –
- Dividend yield
- –
Alpha Cognition Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Product, net | $6.79M | – | 66.5% | – |
| Licensing | $3.43M | – | 33.5% | – |
| Licensing [Member] | $598.43K | – | 5.9% | – |
By region
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| United States | $6.79M | – | 66.5% | – |
| China | $3.43M | – | 33.5% | – |
From the segment and revenue-disaggregation notes of Alpha Cognition's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.